

Call for proposals

To fulfil the Mission's mandate the proposals are sought through an open call (Request for proposals, RFP) published in leading national dailies or in some cases also through top-down selection based on landscape analysis. The following calls were announced to support the NBM goals.

Financial Year 2017-2018: BIRAC announced the following call for proposals under National Biopharma Mission.

FIRST CALL: Biotherapeutics, Vaccines, Medical Devices and Diagnostics

- **Biotherapeutics**
 1. *Product Development*: Biosimilar/biologics products for cancer, diabetes and Rheumatoid arthritis.
 2. *Establishment of Process Development Lab*: To enable development and manufacturing of cost effective bio-therapeutics.
 3. *Establishment of Chemistry Manufacturing Control Unit*: GMP compliant CMC units.
 4. *Establishment of cGMP validation facility for Bio therapeutics*: for characterization and validation of bio therapeutics (therapeutic proteins and monoclonal antibodies).
 5. *Establishment of Cell line Repository*: To create a GMP-compliant Cell Line Repository for providing low cost access to academia and manufacturers of cell lines (Mammalian, microbial) and expression systems that are tested, validated and well characterized.
- **Vaccines**
 1. Novel vaccine candidates for HPV, Dengue and Pneumococcal.
- **Medical Devices and Diagnostics**
 1. Development of medical devices and diagnostics.

Financial Year 2018-2019: BIRAC announced the following call for proposals under National Biopharma Mission.

Second Call: GCLP labs and TRC

1. **Good Clinical Practice Laboratory (GCLP) for Vaccine Clinical Immunogenicity Evaluation**: To address the demands of vaccine developers in assessing the clinical immunogenicity of vaccine candidates in clinical trials so as to submit data to regulatory agencies.
2. **Translational Research Consortia**: To establish consortia that would ensure a translational ecosystem to improve standardised and provide support for advancing development and evaluation of vaccines and monoclonal antibodies for Dengue, Influenza, Chikungunya and RSV.

Third Call: Medical Devices and Med-Tech Facilities

3. Development of products in Medical devices and diagnostics and establishment of Med-tech facilities for testing Electro-Magnetic Interference (EMI/EMC), Medical Lasers, Medical device rapid prototyping, and for biological and preclinical testing.

Fourth Call: Biotherapeutics product development

4. **Biosimilar Product development/Clone development:** Development of cost effective, safe and efficacious Biosimilar product/clone with high market scope to address India's disease burden and development.
5. **Shared facilities for biotherapeutics and cell line repository:** To create GLP compliant analytical facility, GMP manufacturing facility and a GMP-compliant Cell Line Repository for providing access of cell lines and expression systems that are tested and well characterized.
6. **Novel cell line development:** Establishment of a platform technology for production of biopharmaceuticals.